Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:17 PM
Ignite Modification Date:
2025-12-26 @ 10:17 PM
NCT ID:
NCT00022412
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed localized adenocarcinoma of the prostate
* Candidate for prostatectomy
PATIENT CHARACTERISTICS:
Age:
* 21 and over
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* WBC at least 4,000/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic:
* Bilirubin no greater than 1.4 mg/dL
* AST no greater than 3 times normal
Renal:
* Creatinine no greater than 2.0 mg/dL
* Calcium no greater than 10.2 mg/dL
* No idiopathic urinary calcium stone disease
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* Not specified
Endocrine therapy:
* No prior hormonal therapy for prostate cancer
* No concurrent hormonal therapy, including luteinizing hormone-releasing hormone agonists, antiandrogens, glucocorticoids, ketoconazole, finasteride, diethylstilbestrol, or progestins
Radiotherapy:
* No prior brachytherapy or external beam radiotherapy for prostate cancer
Surgery:
* See Disease Characteristics
Other:
* At least 7 days since prior vitamin D therapy or calcium supplements
* No other concurrent vitamin D analogues or calcium supplements
* No concurrent magnesium-containing antacids
* No concurrent thiazide-containing diuretics
* No concurrent phenytoin, phenobarbital, glutethimide, digoxin, or digitalis
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
21 Years
Maximum Age:
120 Years
Study:
NCT00022412
Study Brief:
Protocol Section:
NCT00022412